Asklepios BioPharmaceutical Patents – Key Insights and Stats

Asklepios BioPharmaceutical has a total of 281 patents globally, out of which 38 have been granted. Of these 281 patents, more than 71% patents are active. The United States of America is where Asklepios BioPharmaceutical has filed the maximum number of patents, followed by Europe and United Kingdom. Parallelly, The United Kingdom seems to be the main focused R&D center and also USA is the origin country of Asklepios BioPharmaceutical.

Asklepios BioPharmaceutical was founded in 2001. The Company operates as an AAV gene therapy company. The Company offers end-to-end gene therapy platform includes scaled-up manufacturing with its Pro10 cell line, AAV capsid library and clinical programs for a range of genetic disease indications.

Do read about some of the most popular patents of Asklepios BioPharmaceutical which have been covered by us in this article and also you can find Asklepios BioPharmaceutical patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Asklepios BioPharmaceutical patent portfolio.

How many patents does the Founder and CEO of Asklepios BioPharmaceutical have?

The Founder Jude Samuski has 0 patent, R. Jude Samulski has 5 patents and Sheila Ann Mikhail has 0 patents and the CEO Gustavo Pesquin has 0 patent.

How many patents does Asklepios BioPharmaceutical have?

Asklepios BioPharmaceutical has a total of 281 patents globally. These patents belong to 65 unique patent families. Out of 281 patents, 201 patents are active.

How Many Patents did Asklepios BioPharmaceutical File Every Year?

Asklepios BioPharmaceutical Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantAsklepios BioPharmaceutical Applications FiledAsklepios BioPharmaceutical Patents Granted
2023156
2022235
2021701
202062
2019442
2018195
20171
201626
201535
201491
20132
2012131

How many Asklepios BioPharmaceutical patents are Alive/Dead?

Worldwide Patents

Asklepios BioPharmaceutical Patent Portfolio

 How Many Patents did Asklepios BioPharmaceutical File in Different Countries?

Asklepios BioPharmaceutical Worldwide Patent Filing

Countries in which Asklepios BioPharmaceutical Filed Patents

CountryPatents
United States Of America35
Europe34
United Kingdom31
Hong Kong (S.A.R.)24
Canada20
China20
Australia19
Israel11
Japan7
Germany5
Austria5
New Zealand5
Spain4
South Africa4
Korea (South)4
Singapore2
Mexico2
India1
Brazil1
Taiwan1
Philippines1
Finland1
Russia1
Italy1
Indonesia1

Where are Research Centers of Asklepios BioPharmaceutical Patents Located?

R&D Centers of Asklepios BioPharmaceutical

 10 Best Asklepios BioPharmaceutical Patents

US7001761B2 is the most popular patent in the Asklepios BioPharmaceutical portfolio. It has received 55 citations so far from companies like Sarepta Therapeutics, Bamboo Therapeutics and Solid Biosciences.

Below is the list of 10 most cited patents of Asklepios BioPharmaceutical:

Publication NumberCitation Count
US7001761B255
US8198421B220
US7510867B218
WO2016181171A19
WO2020102645A17
US20030190746A15
WO2018138371A15
WO2015148454A15
US8632765B24
WO2012101191A14

What Percentage of Asklepios BioPharmaceutical US Patent Applications were Granted?

Asklepios BioPharmaceutical (Excluding its subsidiaries) has filed 19 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 8 have been granted leading to a grant rate of 72.73%.

Below are the key stats of Asklepios BioPharmaceutical patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for Asklepios BioPharmaceutical?

Law FirmTotal ApplicationsSuccess Rate
Ronald I Eisenstein1688.89%
Moore & Van Allen20.00%
K&L Gates10.00%

What are Asklepios BioPharmaceutical key innovation segments?

What Technologies are Covered by Asklepios BioPharmaceutical?

The chart below distributes patents filed by Asklepios BioPharmaceutical in different countries on the basis of the technology protected in patents. It also represents the markets where Asklepios BioPharmaceutical thinks it’s important to protect particular technology inventions.

R&D Focus: How has Asklepios BioPharmaceutical search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Asklepios BioPharmaceutical?

Related Articles

VoxelSensors Patents – Insights & Stats (Updated 2024)

VoxelSensors has a total of 36 patents globally, out of which 8 have been granted. Of these 36 patents, more than 94% patents are active. Europe (EPO) is where VoxelSensors has filed the maximum number of patents, followed by China and Israel. Parallelly, Belgium seems to be the main focused

Read More »

Alphapharm Patents – Insights & Stats (Updated 2024)

Alphapharm has a total of 108 patents globally, out of which 43 have been granted. Of these 108 patents, more than 18% patents are active. Australia is where Alphapharm has filed the maximum number of patents, followed by Europe (EPO) and United States of America. Parallelly, Australia seems to be

Read More »

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.